{"id":"NCT00402363","sponsor":"GlaxoSmithKline","briefTitle":"Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11","primaryCompletion":"2010-01","completion":"2010-01","firstPosted":"2006-11-22","resultsPosted":"2010-10-15","lastUpdate":"2017-01-30"},"enrollment":663,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Fibrillation, Atrial"],"interventions":[{"type":"DRUG","name":"omega-3-acid ethyl esters","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"omega-3-acid ethyl esters","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate efficacy and safety of Omacor (omega-3-acid ethyl esters) in patients with recurrent, symptomatic atrial fibrillation.","primaryOutcome":{"measure":"Number of Participants With Paroxysmal AF With an Event of Documented Symptomatic Atrial Fibrillation (AF)/Flutter","timeFrame":"From first dose of study drug (Day 1) to the first symptomatic recurrence of AF/flutter (up to Week 24)","effectByArm":[{"arm":"Paroxysmal AF, Placebo","deltaMin":129,"sd":null},{"arm":"Paroxysmal AF, P-OM3","deltaMin":135,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.263"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":178,"countries":["United States"]},"refs":{"pmids":["21078810","19619690"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":331},"commonTop":["Nausea","Urinary tract infection","Dizziness","Sinusitis","Diarrhea"]}}